Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on BELLUS HEALTH INC. We currently have 16 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
BELLUS HEALTH INC
BELLUS HEALTH INC
BELLUS Health – Taking Stock
15 Aug 16
It has now been nearly two months since BELLUS Health announced that its lead candidate KIACTA™ had not met its primary endpoint in the Phase 3 study completed earlier this year. The shares are 89% down since the news. The company’s recent Q3 release however tells us Shigamab™, a wholly owned programme, has shown further very strong pre-clinical data for sHUS this time in a primate model, and reminds us that BELLUS Health holds interests in a number of third party programmes that have potential we believe not currently reflected in the share price.
Where next for BELLUS Health?
21 Jun 16
The drug development company focused on rare diseases has announced top-line Phase 3 results of KIACTA™ for the treatment of AA amyloidosis. Disappointingly the study did not meet its primary efficacy endpoint (ie shown to have delayed defined adverse events at a P value of 0.05 or less) but was shown to be safe and well tolerated over treatment periods of greater than 4 years. The shares fell 79% on the day to C$0.51.
Countdown to D Day
16 May 16
The drug development company focused on rare diseases last week reported financial and operating results for the quarter ending 31 March. The numbers in themselves contained no surprises. The company made a loss of C$724k vs C$46k in Q1 2015, with the increased loss pertaining largely to a lower level of revenue recognised for accounting purposes in 2016 in relation to the VIVIMIND™ license agreement with FB Health, an increase in general and administrative costs to C$988k from $719k as well as an increase in foreign exchange loss.
Lifesciences Review - Down but not out
21 Mar 16
Stocks in the life sciences industry have struggled to regain their sparkle following the autumn 2015 sell off triggered by Hilary Clinton’s comments on drug pricing with the NASDAQ Biotechnology Index down some 22% since the beginning of the year. Indeed both sides of the presidential race have now targeted pharmaceutical companies with Donald Trump campaigning for price negotiations between drug manufacturers and Medicare
FY2015 results reveal small profit but focus now on vital Q2 KIACTATM data
04 Mar 16
Last week the drug development company focused on rare diseases reported its results for the year ended December 2015. Revenues of C$4m exceeded our C$2.5m expectation. This was due to a higher amount of revenues recognised under the service agreement with the company’s partner on KIACTATM Auven Therapeutics and VIMINDTM license agreement with FB Health. However it should be noted that the cash element of these revenues totaled C$1.3m. On that same basis the company also beat our projections in terms of profitability with a total net profit attributable to shareholders of C$202k compared to a $1.9m loss in FY2014. Year end cash and equivalents of $9.7m were in line with our expectations giving the company some headroom to advance its earlier stage programmes in the event that no deal is struck for KIACTATM this year.
Phase 3 confirmatory trial complete
22 Jan 16
BELLUS Health and its partner Auven therapeutics have announced that the KIACTATM event-driven phase 3 confirmatory study for the treatment of AA amyloidosis, has met its completion target of 120 patient events linked to the deterioration of kidney function. Top line data will take a few months to be compiled after all remaining patients have completed final study visits. The trial has spanned 50 sites worldwide. It is only once this process is complete that the data from the placebo controlled trial will be unblinded and all stakeholders (the company, its shareholders, clinicians and AA amyloidosis sufferers) will know whether the study has met with its primary endpoint which will support global regulatory approvals. The initial results are expected to be released in the second quarter of this year.
N+1 Singer - Morning Song 21-03-2017
21 Mar 17
accesso Technology (ACSO LN) Full year results in line, but key trading months still ahead | Augean (AUG LN) Double digit growth in ’16, good start to ‘17 | Earthport (EPO LN) Interims show continued top line strength | Goals Soccer Centres (GOAL LN) Good momentum under new team. It’s now all about delivery | IQE (IQE LN) FY’16 results prompt further upgrades | Microsaic Systems (MSYS LN) Challenges in 2016, strategy remains in place | mporium Group (MPM LN) Funds raised to help execute strategy | RhythmOne (RTHM LN) Dawn of the independents | ScS Group (SCS LN) Strong progress on key growth initiatives albeit comps now toughen | Sinclair Pharma (SPH LN) FY results: EBITDA ahead, Instalift™ gaining pace | Vectura Group (VEC LN) FY (9-month) results
Interim results lead to upgrades
27 Mar 17
Bioventix reported a strong set of interim results with revenues increasing by 32% (c.12-17% at constant exchange rates (CER)), driven largely by the continued roll-out of its customers’ Vitamin D assay products. This, in turn, led to a 41% increase in pre-tax profits and a 40% increase in adjusted EPS; which is reflective of the operational gearing of the business. We are upgrading our adjusted EPS to 78.7p (+5%) and, consequently, are raising our target price to 1750p. At this price level, the shares would trade on a 22.4x FY 2018 P/E and an EV/EBITDA of 17x. We await confirmation of Siemen’s high sensitivity troponin assay launch, expected in FY 2018.
27 Mar 17
Elecosoft* (ELCO): Steadily building profits (CORP) | Bioventix* (BVXP): Interim results lead to upgrades (CORP) | Hurricane Energy (HUR): Halifax discovery (BUY) | KBT Business Technology* (KBT): interims and contract win (CORP) | Independent Oil & Gas* (IOG): Licence updates (CORP)
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
Sinclair Pharma - Aesthetically Positioned to Continue Double-Digit Growth
23 Mar 17
With an innovative and differentiated product portfolio of injectable devices addressing the fast-growing aesthetics market, Sinclair is best positioned to continue to achieve double-digit revenue growth in the medium term.
N+1 Singer - Futura Medical - Licensing deal for CSD500 in Portugal
22 Mar 17
The agreement with F Lima further extends the market reach of CSD500, Futura’s erectogenic condom, and brings the total number of distribution partners to eight. The deal is in line with the company’s stated strategy of partnering with leading regional players in the consumer products space. We expect the condom to be launched in Portugal later this year. We retain a positive stance.